Predictors of fatigue following the onset of infectious mononucleosis by Candy, B et al.
Predictors of fatigue following the onset of
infectious mononucleosis
B. CANDY, T. CHALDER, A. J. CLEARE, A. PEAKMAN, A. SKOWERA,
S. WESSELY, J. WEINMAN, M. ZUCKERMAN AND M. HOTOPF1
From the Department of Psychological Medicine, Department of Immunology, Public Health Laboratory and
Medical Microbiology, Guy’s, King’s and St Thomas’ School of Medicine and Institute of Psychiatry, London
ABSTRACT
Background. Infectious mononucleosis (IM) is a risk factor for chronic fatigue. Reduced activity is
the most consistent factor found to be associated with poor outcome following the onset of infec-
tious mononucleosis. However, little is known about the biological mechanisms involved in the
pathogenesis of chronic fatigue following IM and no study, so far, has examined the relation
between certain illness beliefs and poor outcome. This study explored immunological, endocrine,
behavioural and cognitive responses to the acute illness and assessed which components of these
groups of risk factors predicted a chronic course.
Method. Using a prospective cohort design, 71 primary care patients with IM were enrolled onto
the study and interviewed. Their recovery was explored by postal questionnaire up to 1 year later.
Results. In the univariate analysis, increased baseline levels of immune activation were associated
with fatigue at baseline and 3 months. Cortisol levels were not associated with fatigue at any point.
Using multivariate models of clinical and psychosocial baseline factors, severity of symptoms and
illness perceptions were found to predict fatigue 3 months later. At 6 months, fatigue was best
predicted by female gender and illness perceptions, and at 12 months by female gender and a
symptoms–disability factor.
Conclusions. In the multivariate analysis no factors were found to predict poor outcome at all time-
points. Instead the pattern of predictors changed over time, partly but not completely consistent
with our a priori predictions. Larger studies are needed to explore further the predictive nature of
biopsychosocial factors in the pathogenesis of chronic fatigue related to IM. The psycho-behav-
ioural predictors found in this study are amenable to intervention. Such interventions should be
tested in randomized controlled trials.
INTRODUCTION
There is substantial evidence that infectious
mononucleosis (IM), often referred to as glandu-
lar fever, and other severe viral infections are risk
factors for chronic fatigue (Berelowitz et al.
1995; Hotopf et al. 1996; Buchwald et al. 2000;
White et al. 2001). White’s cohort study dem-
onstrated a ﬁve-fold increase in chronic fatigue
among individuals suﬀering from IM compared
with controls that had suﬀered upper respirat-
ory tract infections (White et al. 1998). There
are a number of possible mechanisms that could
explain this association. Psycho-behavioural
mechanisms have been postulated for fatigue
following severe infections, and there is some
evidence that individuals who have a history
of previous psychiatric disorder (Hotopf et al.
1996) ; physical attributional style (Cope et al.
1994) ; greater adverse life events (Buchwald
et al. 2000) ; greater family support (Buchwald
et al. 2000) ; and lower ﬁtness (White et al. 2001)
are at greater risk of poorer outcomes. In a
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recent systematic review the most consistent
factor found for delayed recovery in IM was
reduced physical functioning (Candy et al. 2003).
Thus, these cognitive and behavioural factors
might predict a pattern of response that leads to
deconditioning, which is an important candi-
date for perpetuating fatigue. More distal pre-
dictors of an individual’s response to illness may
also be important, and we have recently shown
that unexplained symptoms in adulthood are
associated with childhood experiences of illness
(Hotopf et al. 1999, 2000).
There are also a range of important biological
candidate mechanisms for the association be-
tween glandular fever and chronic fatigue. One
possibility is the immune response associated
with glandular fever, and White and colleagues
(2001) found that acute fatigue was associated
with a raised CD8 cell count. There is con-
siderable evidence that immune function may be
altered in chronic fatigue, but there is no con-
sistent pattern of immune proﬁle associated with
the condition (Wessely et al. 1998). It is import-
ant, therefore, to determine whether immune
changes that occur in illnesses that may precipi-
tate chronic fatigue syndrome (CFS) contribute
to subsequent fatigue.
CFS is also associated with alterations in
neuroendocrine function, with a relative under
activity of the hypothalamic–pituitary–adrenal
axis (HPA) (Cleare et al. 2001; Parker et al.
2001). While this seems a robust ﬁnding in in-
dividuals with established CFS, without pro-
spective studies of individuals at high risk of
developing CFS it is diﬃcult to tell whether
such changes play a causal role, or are a result
of downstream factors such as sleep, decon-
ditioning or circadian rhythm disruption (Spath
Schwalde et al. 1992; Stupnicki & Obminski,
1992; Leese et al. 1996).
Aims and hypothesis
This study aimed to bring together diverse bio-
logical and psychological risk factors in study-
ing the pathogenesis of chronic fatigue related
to IM. The study tested the following hypoth-
eses.
1 Increases in immune activation are associ-
ated with severity of acute fatigue. Such immune
activation does not predict chronic fatigue.
2 Individuals with lower salivary cortisol at
baseline would be at greater risk of developing
chronic fatigue. Chronic fatigue at follow-up
would also be associated with reduced salivary
cortisol concentrations.
3 A range of behavioural and psychologi-
cal factors at baseline will predict subsequent
fatigue: these include childhood experience of
chronic illness, physical attributional style, ill-
ness perceptions that perceived the illness as
having serious consequences, and a reduction in
activity.
METHOD
Recruitment
Potential participants were identiﬁed by positive
IM serology from three haematology and two
virology laboratories, and by six general prac-
tices and one student health centre. First contact
with the patient was made by their GP and only
on agreement were they approached and invited
to participate by the researcher. If they agreed
to participate they were asked for an interview
in their own home as soon as possible. Patients
were all invited to participate in a randomized
controlled trial of a brief psycho-educational
intervention, or usual care. The results of this
randomized trial have been reported elsewhere
(Candy et al. 2003). We aimed to gain a con-
secutive sample of all patients positive for IM
from the laboratories. Eﬀorts were made to
remind clinicians in the general practices and
student health centre about the study, but it is
likely that a proportion of cases of IM will have
been missed.
Participants
The inclusion criteria were: (1) aged between 16
and 45 years ; (2) clinically diagnosed IM; and
(3) serological evidence of recent IM either from
a heterophile antibody test (Microgen Biopro-
ducts Ltd, UK) or by using the VCA IgM im-
munoﬂuorescence assay (Immuno concepts Inc,
Sacramento, CA). Patients with IM were not
eligible if they were reported by the GP to have
additional physical illnesses that may be associ-
ated with fatigue (such as endocrine disorders).
Patients with psychotic illnesses (schizophrenia
and bipolar disorder) and substance misuse
were also excluded, as were individuals who had
limited literacy skills as most of the variables
were measured using questionnaires. In practice
this did not lead to any exclusions.
848 B. Candy and others
Baseline data
Whole blood was collected (into EDTA) to
measure activated CD4 helper and CD8 cyto-
toxic T cells. Activation was assessed by surface
expression of the marker HLA-DR and meas-
ured by ﬂow cytometry using speciﬁc mono-
clonal antibodies. Activated CD4 and CD8 T
cells were measured as the percentage of each
population co-expressing the class II HLA
molecule HLA-DR, a well-recognized marker of
chronically activated T cells.
Participants were asked to give four saliva
samples on a single day using the salivette (Sar-
stedt, UK) collection system. Sample times were
08.00, 12.00, 16.00 and 20.00 h. Subjects were
asked to not eat or drink anything in the hour
before collection, and to sit or lie down for
20 min before they collected their sample. Wo-
men were also asked to collect their saliva only
within the ﬁrst week of their menstrual cycle.
We measured the cortisol concentration in each
sample to gain an overall measure of HPA axis
activation across the day.
At baseline participants completed a range of
questionnaires. Fatigue was measured on the
Chalder Fatigue Questionnaire (Chalder et al.
1993) an 11-item fatigue scale. Each item con-
sists of four possible answers that can either be
scored 0/1 or 0, 1, 2, 3. The former system is
used to generate a case deﬁnition (>3), the latter
is used to generate a continuous fatigue score
(0–33). Psychological distresswas assessed on the
12-item General Health Questionnaire (GHQ-
12) (Goldberg & Williams, 1988) ; functional
status on the Work and Social Adjustment Scale
(Marks, 1986) and the Short Form-36 (SF-36)
(Garratt et al. 1993) ; social support on the Sig-
niﬁcant Others Scale (Power et al. 1988) ; life
events on the Life Events Inventory (Cochrane
& Robertson, 1973) ; and suﬀerers’ understand-
ing and expectations of current illness on the
Illness Perceptions Questionnaire (Weinman
et al. 1996). Additional questions were asked on
their childhood experience of chronic illness,
their current symptoms and expectations of re-
covery and on any illness advice they were given
by health professionals.
Follow-up data
Participants were also asked to supply saliva
samples at 3 and 6months. Postal questionnaires
at 3 and 6 months repeated measures taken at
baseline. Only the fatigue questionnaire was sent
at 12 months.
Statistical analysis
The main measure of poor outcome was fatigue
caseness, as deﬁned as scoring>3 on the fatigue
questionnaire (Chalder et al. 1993). We also
used fatigue as a continuous variable measured
on the same questionnaire.
In the ﬁrst instance, baseline and follow-up
fatigue symptoms (measured as a continuous
variable) were correlated with baseline immune
activation. Results were expressed as percentage
activated CD4 or CD8 cells.
The main parameter used to indicate cortisol
proﬁles at each time point was the total output
calculated as area under the curve (AUC) using
the trapezoidal method. In addition, we took
four secondary measures: peak value (highest of
the four samples), trough value (lowest of the
four samples), mean value (mean of the four
samples), and the diurnal change (peak minus
trough). These measures were compared with
those from a healthy control group of similar
age (mean=22.6 years). In order to explore the
possible relationship of these parameters with
fatigue, we undertook cross sectional analyses at
baseline, 3 months and 6 months, and a pro-
spective analysis of whether baseline cortisol
parameters were associated with fatigue at 3 and
6 months.
The relationships between psycho-behav-
ioural baseline variables and fatigue caseness at
baseline, 3, 6 and 12 months were determined
using odds ratios and 95% conﬁdence intervals.
Logistic regression analysis was used to control
for potential confounders. For each time point,
we determined the relationship between baseline
characteristics and fatigue. The analytical strat-
egy we used was ﬁrstly to determine whether
socio-demographic factors (age and gender), as
well as treatment group, were associated with
fatigue at each time point. All analyses were
controlled for treatment group. If age or gender
was not associated at P<0.2 they were not in-
cluded in subsequent analyses. The next step was
to add baseline clinical characteristics (symp-
toms and disability/functionality), and again if
these were not signiﬁcantly associated they were
not included further. Finally, illness perceptions
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were added and controlled for the eﬀects of
baseline clinical variables.
RESULTS
Seventy-one (51%) of 139 referred primary care
patients agreed to participate. None of the par-
ticipants were excluded due to being over 45
years, having psychotic illness or substance
misuse. The most common reason for non-par-
ticipation was inaccurate contact details held by
the laboratory or general practice. Participants
were compared with non-participants on age,
gender and location (inner city or not) of the
general practice at which they were registered.
This revealed similarity in age and practice lo-
cation, but males were less likely to participate
(39% v. 54%). Of the 71 patients identiﬁed, all
had a positive monospot test. EBV serology was
available on 41 cases, in whom 36 (88%) were
positive for EBV IgM.
Sixty-nine per cent of those who participated
responded to follow-up at 3 months, 87% at
6 months and 70% at 12 months. There were no
diﬀerence in age, sex or baseline fatigue scores
between responders and non-responders at
6 months. At 12 months, non-responders were
more likely to be women (P=0.09) and older
(P=0.09), but there were no diﬀerences in
baseline fatigue status. Due to technical diﬃcult-
ies blood samples were received for immuno-
logical analysis from 45% of the sample. Saliva
samples for cortisol analysis were returned by
66% of participants.
Baseline characteristics
Characteristics of patients are shown in Table 1.
The sample was generally young, just under half
were students and most were single. The median
time from onset of symptoms to ﬁrst assessment
was 38 days. There was no association between
level of fatigue at baseline, and time between
onset of symptoms and interview.
At baseline interview 41% (29/71) reported
that fatiguewas their main IM symptom. Eighty-
ﬁve per cent of participants, measured by the
Fatigue Questionnaire (Chalder et al. 1994),
were fatigue cases ; 4% reported that fatigue
had lasted>6 months and 68% reported not to
have recovered. Table 2 shows the fatigue status
at follow-up. Over time, fewer participants were
fatigue cases, more had recovered, and more
reported that their fatigue had lasted >6
months.
Univariate analysis
Immune activation
During the acute phase (within 6 weeks of onset
of IM) those deﬁned as fatigue cases had a
higher percentage of activated CD4 lympho-
cytes compared to those who were not cases,
(median, 13.2% v. 6.2,Mann–WhitneyU=9.00,
P=0.025, N=21). There was a higher percent-
age of activated CD8 lymphocytes in fatigue
cases compared with non-fatigue cases (median
53.8% v. 25.5%; Mann–Whitney U=7.00,
P=0.016, N=21). Fatigue cases at 3 months
also had higher acute phase percentages of ac-
tivated CD4 (median 25.6% v. 9.9%, Mann–
Whitney U=5.0, P=0.02, N=14). Similarly,
Table 1. Characteristics of sample at baseline
assessment
Female
Mean age (S.D.)
60%
22.9 (8.2)
Student 46%
Living with parent or partner 68%
History of emotional problems 20%
Days from onset to ﬁrst assessment 38 (IQR: 29–60)
GP diagnosed IM at ﬁrst consultation 27%
Days oﬀ sick 10 (IQR: 5–16)
GHQ score (S.D.) 16.7 (6.2)
Physical functioning SF-36 (S.D.) 79.6 (22.4)
Physical functioning in last month
SF-36 (S.D.)
20.8 (34.8)
Emotional functioning in last month
SF-36 (S.D.)
56.5 (42.2)
Work and Social Adjustment Scale score (S.D.) 8.8 (8.5)
Believed recovery will take>1 month 24%
IPQ control cure (S.D.) 20.3 (3.3)
IPQ consequences (S.D.) 19.2 (4.5)
Fatigue score (S.D.) 19.9 (5.2)
Case of fatigue 85%
Fatigue for>6 months 4%
Not recovered from IM 68%
Table 2. Fatigue status at follow-up
3 months
N=49
6 months
N=62
12 months
N=50
Fatigue score 15.5 (5.6) 14.1 (4.5) 14.1 (5.0)
Fatigue case 47% 40% 38%
Fatigue lasting
>6 months
14% 11% 5%
Not recovered
from IM
45% 38% NA
NA, Not assessed.
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fatigue cases at 3 months had higher activated
CD8 counts at baseline compared with non-
fatigue cases (median, 79.1% v. 42.1%; Mann–
Whitney U=7.00, P=0.039, N=14). Fatigue at
6 months was also associated with higher base-
line activation of CD4 and CD8 counts, but this
diﬀerence did not reach statistical signiﬁcance.
Because of the small number of samples gained
these factors were not explored in multivariate
analysis.
Cortisol measures
There were no diﬀerences in any of the ﬁve
cortisol parameters between fatigue cases and
non-cases when analysed cross sectionally at
baseline, 3 months and 6 months. The AUC
values were 95.5 (S.D. 31.8) nmol/l/h in cases and
90.1 (S.D. 14.6) nmol/l/h in non-cases (t=0.34,
P=0.74) at baseline, 93.8 (S.D. 31.1) nmol/l/h in
cases and 79.4 (S.D. 27.4) nmol/l/h in non-cases
(Mann–WhitneyU=97.00,P=0.35) at 3months
and 88.8 (S.D. 24.2) nmol/l/h in cases and 83.4
(S.D. 39.6) nmol/l/h in non-cases (t=0.43, P=
0.67) at 6 months. Similarly, there were no sig-
niﬁcant correlations between fatigues scores and
cortisol parameters at baseline, 3 or 6 months.
We also categorized subjects into low or high
AUC using the lowest AUC quartile to deﬁne a
low cortisol state. Those with low AUC cortisol
values had similar fatigue scores to those with
high values at both baseline (low AUC, 20.2
(4.1) points ; high AUC, 19.8 (5.5) points,
t=0.20, P=0.84) and at 6 months (low AUC,
11.4 (2.8) points ; high AUC, 14.4 (4.6) points,
t=1.67, P=0.1). Using the same analysis we
compared baseline cortisol parameters for all
participants, and for the subgroup who were
deﬁned as fatigue cases at baseline, with the
control group. We found no signiﬁcant diﬀer-
ences.
In the prospective analysis, the change in
AUC cortisol between baseline and 6 months
was not related to fatigue caseness at 6 months.
The mean change score for those with fatigue
caseness at 6 months was 4.7 (S.D. 35.1) and in
non-cases 8.9 (S.D. 40.9) (Mann–Whitney U=
79.5, P=0.40). Those with low baseline AUC
values did not diﬀer in their fatigue scores at 6
months follow-up from those with high baseline
AUC values (low AUC, 14.9 (5.7) points ; high
AUC, 13.9 (4.3) points, t=0.62, P=0.53).
Behavioural and psychological factors
Table 3 gives the univariate odds ratios and
conﬁdence intervals for the hypothesized vari-
ables. At baseline, lower socio-economic group,
and clinical features including having worse
symptoms, lower physical functioning, and a
higher general health questionnaire (GHQ)
score were associated with fatigue caseness. By
3 months, fatigue caseness was predicted by a
history of emotional problems, clinical features,
a longer convalescence, baseline fatigue score, a
belief that their recovery will take more than
1 month and that IM would have serious conse-
quences on their life. At 6 months being female,
lower functionality and a belief at baseline that
IM would have more serious consequences on
their life (illness perception questionnaire (IPQ)
consequences subscale) predicted fatigue case-
ness. Baseline functionality, and level of symp-
toms were associated with fatigue caseness
12 months later.
Multivariate models
We used logistic regression analyses to model
the eﬀects of independent variables on fatigue
cases. Because there were a wide range of po-
tential baseline variables measuring symptoms
and disability, we used a varimax factor analysis
to reduce these variables to a smaller number of
factors. The variables entered into the analysis
were baseline total symptom score (i.e. ameasure
of the severity of the acute symptoms of glandu-
lar fever), GHQ score, SF36 scores (three sub-
scales), Work and Social Adjustment Scale
(WSAS), and total fatigue score. The analysis
yielded a two factor solution (see Table 4).
Factor one (symptoms–disability) was loaded
heavily by total physical symptoms, physical
functioning on the SF36 and WSAS score.
Factor two (fatigue–depression) comprised total
fatigue and GHQ scores at baseline. These fac-
tors were standardized to generate a mean of
0 and a standard deviation of 1.
Table 5 shows the results of the logistic re-
gression analysis. At 3 months, the strongest
predictors of fatigue were total symptoms at
baseline and the belief that they will take
>1 month to recover from IM. At 6 months,
female gender was associated with fatigue, as
were illness perceptions (both the beliefs that the
illness would take >1 month to recover from
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and that the illness would have more serious
consequences (IPQ subscale)). By 12 months,
the main predictor was increasing age, female
geneder and symptoms–disability at baseline;
illness perceptions were no longer associated.
Similar analyses were performed using multiple
regression analysis, with fatigue as a continuous
outcome as the dependent variable. This yielded
similar results (results not shown).
DISCUSSION
Our results indicate that fatigue at 3 months is
strongly predicted by the severity of baseline
symptoms, the belief that the illness will take
>1 month to recover from, and immune acti-
vation. By 6 months, the main predictors are
illness perceptions at baseline, but at 12 months
older age and female gender are the key pre-
dictors, as well as a weaker eﬀect of baseline
symptoms. At no point were cortisol levels re-
lated to fatigue.
Before addressing these ﬁndings in more de-
tail it is necessary to make some general com-
ments on the methodology. First, this was a
pilot study with a small sample size, which may
have resulted in type two errors. For example,
the association between immune activation and
fatigue at 3 months, but not later, does not rule
out the possibility of an association with later
fatigue. Secondly, the follow-up rates at 3 and
12 months were disappointing. The most robust
ﬁndings were those at 6 months where the best
follow-up was achieved. Thirdly, the results
were taken from within a randomized controlled
trial, and it is possible that the intervention itself
Table 4. Results of factor analysis
Variable
Symptoms–
disability
Fatigue–
depression
SF-36 Physical functioning x0.74*
SF-36 Physical functioning
SF-36 Emotional function
WSAS 0.77
Baseline fatigue 0.41 0.60
Severity of physical 0.67 0.41
symptoms 0.66
GHQ score
WSAS, Social andWork Adjustment Scale ; GHQ, General Health
Questionnaire ; SF-36, Short form 36.
Results only shown if rotated factor loading >0. * SF-36 factor
loading is negative because high score indicates good functioning.
Table 3. Univariate odds ratios (95% CI ) for baseline associations with fatigue at four time points
Baseline 3 months 6 months 12 months
N fatigue cases/N completed assessment 60/71 23/49 25/62 19/50
Sociodemographic features
Female gender 2.1 (0.6–7.6) 2.0 (0.6–6.4) 3.8 (1.3–12.3) 2.7 (0.7–10.6)
Student 0.4 (0.2–1.7) 0.9 (0.3–2.8) 0.8 (0.3–2.3) 0.8 (0.3–2.7)
Age>19 years* 0.5 (0.1–2.0) 0.6 (0.2–2.0) 0.9 (0.3–2.4) 0.5 (0.2–1.7)
Non-manual occupation 0.2 (0.4–0.9) 0.4 (0.1–1.4) 0.9 (0.3–2.4) 1.2 (0.4–3.8)
Lives with parent or partner 0.8 (0.2–3.1) 0.5 (0.1–1.6) 0.6 (0.2–1.8) 0.4 (0.1–1.4)
More than one recent adverse life event 3.9 (0.8–19.8) 1.5 (0.5–4.6) 1.2 (0.4–3.4) 2.4 (0.7–7.7)
Childhood experience of illness in family 0.6 (0.2–2.1) 1.8 (0.5–5.7) 2.8 (0.9–8.1) 2.1 (0.6–6.8)
Past history of emotional problems NA 6.4 (1.2–34.3) 1.4 (0.4–4.6) 3.0 (0.8–11.5)
Does regular sport 1.1 (0.3–4.1) 0.9 (0.3–2.8) 0.7 (0.2–2.1) 1.1 (0.4–3.4)
Features of glandular fever at baseline assessment
o10 days oﬀ sick NA 4.0 (1.1–14.4) 1.1 (0.3–3.8) 1.2 (0.3–4.9)
‘Recovered’ at interview 0.5 (0.1–2.0) 0.2 (0.3–0.9) 0.9 (0.3–2.7) 0.6 (0.2–2.3)
Given advice to rest by GP 0.6 (0.2–2.5) 0.6 (0.2–1.9) 1.3 (0.4–3.9) 0.8 (0.2–2.7)
High total symptom* 4.4 (1.0–18) 8.6 (2.0–37) 1.6 (0.5–4.7) 5.7 (1.4–24)
High symptoms severity* 14 (1.7–118) 12 (2.8–52) 1.8 (0.6–5.3) 4.8 (1.8–27)
Low physical functioning (SF-36)* 12 (1.5–101) 4.5 (1.3–15) 1.0 (0.4–2.8) 1.5 (0.5–4.6)
Poor physical functioning in last month (SF-36)* 8.0 (1.9–34) 6.7 (1.6–28) 1.3 (0.4–4.3) 1.1 (0.3–4.1)
Poor emotional functioning last month (SF-36)* 4.5 (0.9–22.6) 2.9 (0.9–9.4) 1.3 (0.5–3.5) 0.8 (0.2–2.5)
Poor functioning on WSAS* 17 (2.1–144) 20 (3.8–1.4) 2.7 (0.9–8.0) 6.5 (1.5–27)
GHQ-12>5* 6.3 (1.3–32) 11 (2.7–42) 2.8 (1.0–8.1) 1.1 (0.4–3.6)
Low control/cure (IPQ)* 0.3 (0.1–1.6) 1.6 (0.5–5.1) 0.6 (0.2–1.6) 1.7 (0.5–5.9)
High consequences (IPQ)* 4.0 (1.0–17) 5.8 (1.6–20) 3.0 (1.0–9.0) 1.4 (0.4–4.5)
Expect recovery will take>1 month NA 8.4 (2.0–36) 3.4 (1.1–11) 3.0 (0.9–11)
* Indicates median split used; NA, odds ratio not presented due to empty cells.
SF-36, Short Form 36; WSAS, Work and Social Adjustment Scale ; GHQ-12, General Health Questionnaire ; IPQ, Illness Perceptions
Questionnaire.
Statistically signiﬁcant associations (P<0.05) are shown in bold type.
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aﬀected some of our key predictor variables
such as illness perceptions. We report the results
for the randomized controlled trial separately
(Candy et al. 2003), and we have controlled for
any eﬀect of the intervention in the multivariate
analyses shown here. The intervention would
only bias the results of the present study if there
were interactions between the predictors de-
scribed here and the intervention. We are unable
to test for these interactions due to inadequate
statistical power.
Immune variables
Our ﬁndings are not dissimilar to those of White
et al. (2001) where an association, during the
acute illness phase, between total CD8 T cell
count and fatigue levels was seen, although no
correlations were found with total CD4 and fa-
tigue. In the present study we chose to measure
the activated subsets of CD4 and CD8 T cells,
rather than those of the total populations. We
reasoned that these subsets would be more re-
ﬂective of the degree of immune activation, and
therefore have a stronger relationship with
acute, ‘ immune-mediated’ fatigue. This indeed
proved to be the case, with both activated CD4
and CD8 subsets being associated with acute
fatigue. Like White and colleagues, we did not
ﬁnd any evidence that these immune changes
led to longer-term fatigue, but due to the small
samples in which we had immune data, and
some losses to follow-up this could have been
a type II error.
Cortisol
Our study failed to show any relationship be-
tween fatigue and low cortisol. There was no
link between cortisol levels and fatigue at 0, 3 or
6 months, and those with lower cortisol levels at
baseline were no more likely to go on to develop
fatigue than those with higher levels. There is
now accumulating evidence that patients with
established CFS do have impaired function of
the adrenal axis on some measures (Cleare et al.
2001; Parker et al. 2001). Most of these studies
have been undertaken on participants ill for
several years or longer, with more severe dis-
ability, and with more strictly deﬁned CFS. Our
results suggest that abnormalities in cortisol
may not occur early on in the genesis of chronic
fatigue, and are not a risk factor for chronic fa-
tigue of 6 months duration. It is perhaps more
likely that other factors, perhaps those second-
ary to prolonged fatigue and disability, are re-
sponsible for the observed changes in adrenal
function in those more chronically and severely
ill. Alternatively, those destined to go on to
develop more severe and chronic illness may
indeed have impaired adrenal function but were
too uncommon to have been detected in this
small study.
Illness perceptions
In the multivariate analysis we found that ex-
pectations that the individual would take a long
time to recover, or that the illness would have
serious consequences were associated with a
poorer outcome up to 6 months later. This was
not explained by symptom severity during the
acute phase.
Two previous cohort studies have explored
fatigue following the onset of IM. Buchwald
and colleagues (2000) found self-report of
Table 5. Results of logistic regression analysis
Fatigue case at
Variable 3 months (N=49) 6 months (N=62) 12 months (N=50)
Step 1 variables
Age 1.10 (1.00–1.21)
Female gender 4.54 (1.23–16.8) 4.36 (0.98–19.5)
Step 2 variables
Symptoms–disability 3.11 (1.35–7.17) 2.22 (0.99–5.02)
Fatigue–depression 3.73 (1.41–9.91)
Step 3 variables
Recovery will take>1 month 7.60 (1.11–52) 4.20 (1.11–16.0)
IPQ consequences 1.18 (1.01–1.37)
Parameters are ORs and 95% conﬁdence intervals. For the continuous variables (age, symptoms–disability, fatigue–depression and IPQ
consequences) results indicate the increase in odds associated with each unit increase in the variable.
Predictors of fatigue following infectious mononucleosis 853
non-recovery at 2 months was best determined
by biological factors, whereas the 6 months
predictors represented a more complex mix of
psychological and social factors. In White and
colleagues’ cohort the most reliable predictor of
fatigue syndrome to 6 months after onset was
poorer physical ﬁtness (White et al. 2001), a
variable we did not test in the present study.
These studies explored diﬀerent predictors and
outcomes, but like us they both found that the
predictors of poor outcome depended on when
the outcome was measured. Acute or subacute
fatigue seems to have diﬀerent predictors, poss-
ibly more strongly related to the severity of the
original illness, than chronic fatigue.
Out study is the ﬁrst to explore initial illness
perceptions and subsequent recovery in IM. The
importance of illness perceptions as predictors
of poorer health outcomes has been found for
other conditions (Sharloo et al. 1998; Fortune
et al. 2000; Edwards et al. 2001). We now extend
this to IM. The testing of interventions aimed at
increasing beliefs in personal control and chang-
ing beliefs about the course and the conse-
quences of the illness to help improve outcome
is now underway for various conditions (Clark
& Hampson, 2001; Petrie et al. 2002). The trial
of an intervention to aid recovery in IM that
aimed at promoting certain perceptions and as
well as advising a time-targeted return to normal
activity has been tested by us in an exploratory
study and found to improve medium-term
fatigue levels (to be reported elsewhere). Such
as intervention should be tested in larger ran-
domized controlled trials in IM patients prior to
general implementation.
This study was funded by the Linbury Trust. We
thank Dr Andrew Papadopoulos for undertaking
salivary cortisol assays, and Lucia Poon, the partici-
pating GPs, and staﬀ from the virology and haema-
tology laboratories involved for their assistance in
recruiting patients.
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